JPWO2020048995A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020048995A5 JPWO2020048995A5 JP2021512906A JP2021512906A JPWO2020048995A5 JP WO2020048995 A5 JPWO2020048995 A5 JP WO2020048995A5 JP 2021512906 A JP2021512906 A JP 2021512906A JP 2021512906 A JP2021512906 A JP 2021512906A JP WO2020048995 A5 JPWO2020048995 A5 JP WO2020048995A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- peptides
- peptide
- listed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 229920000023 polynucleotide Polymers 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 229920001184 polypeptide Polymers 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 20
- 102000038129 antigens Human genes 0.000 claims 20
- 108091007172 antigens Proteins 0.000 claims 20
- 210000004027 cells Anatomy 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 8
- 230000001939 inductive effect Effects 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 230000001717 pathogenic Effects 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 claims 2
- 201000005216 brain cancer Diseases 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 210000002443 helper T lymphocyte Anatomy 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 230000002335 preservative Effects 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 230000001413 cellular Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
Claims (21)
(a)表25A及び/又は表25Bに列挙されており、表24に列挙されている乳がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(b)表25A及び/又は表25Bに列挙されており、表24に列挙されている肺がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(c)表25A及び/又は表25Bに列挙されており、表24に列挙されている前立腺がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(d)表25A及び/又は表25Bに列挙されており、表24に列挙されている結腸直腸がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(e)表25A及び/又は表25Bに列挙されており、表24に列挙されている膀胱がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(f)表25A及び/又は表25Bに列挙されており、表24に列挙されている卵巣がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(g)表25A及び/又は表25Bに列挙されており、表24に列挙されている膵臓がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(h)表25A及び/又は表25Bに列挙されており、表24に列挙されている脳がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(i)表25A及び/又は表25Bに列挙されており、表24に列挙されている白血病関連抗原の断片であることが表25A又は25Bに示されている配列;
(j)表25A及び/又は表25Bに列挙されており、表24に列挙されているリンパ腫関連抗原の断片であることが表25A又は25Bに示されている配列;
(k)表25A及び/又は表25Bに列挙されており、表24に列挙されている肝細胞がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(l)表25A及び/又は表25Bに列挙されており、表24に列挙されているメラノーマ関連抗原の断片であることが表25A又は25Bに示されている配列;
(m)表25A及び/又は表25Bに列挙されており、表24に列挙されている甲状腺がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(n)表25A及び/又は表25Bに列挙されており、表24に列挙されている小児がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(o)表25A及び/又は表25Bに列挙されており、表24に列挙されている胃がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(p)表25A及び/又は表25Bに列挙されており、表24に列挙されている腎臓がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(q)表25A及び/又は表25Bに列挙されており、表24に列挙されている頭頸部がん関連抗原の断片であることが表25A又は25Bに示されている配列;
(r)表25A及び/又は表25Bに列挙されており、表24に列挙されている子宮頸がん関連抗原の断片であることが表25A又は25Bに示されている配列。 4. The panel of peptides, polynucleic acids or vectors of claim 3, wherein each peptide or encoded peptide comprises at least one amino acid sequence selected from one of the following groups:
(a) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a breast cancer associated antigen listed in Table 24;
(b) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a lung cancer-associated antigen listed in Table 24;
(c) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a prostate cancer-associated antigen listed in Table 24;
(d) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a colorectal cancer-associated antigen listed in Table 24;
(e) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a bladder cancer-associated antigen listed in Table 24;
(f) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of an ovarian cancer-associated antigen listed in Table 24;
(g) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a pancreatic cancer-associated antigen listed in Table 24;
(h) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a brain cancer-associated antigen listed in Table 24;
(i) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a leukemia-associated antigen listed in Table 24;
(j) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a lymphoma-associated antigen listed in Table 24;
(k) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a hepatocellular carcinoma-associated antigen listed in Table 24;
(l) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a melanoma-associated antigen listed in Table 24;
(m) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a thyroid cancer-associated antigen listed in Table 24;
(n) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a childhood cancer-associated antigen listed in Table 24;
(o) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a gastric cancer-associated antigen listed in Table 24;
(p) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a kidney cancer-associated antigen listed in Table 24;
(q) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a head and neck cancer-associated antigen listed in Table 24;
(r) a sequence listed in Table 25A and/or Table 25B and shown in Table 25A or 25B to be a fragment of a cervical cancer-associated antigen listed in Table 24;
(i)a.各ペプチド若しくはコードされているペプチドが、前記被験体の少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープである少なくとも1つのアミノ酸配列を含んでいると判定し;そして、
b.前記被験体が、前記医薬組成物の各ペプチド、又は前記キットの各ペプチド、ポリ核酸、若しくはベクターに対してCD8+T細胞応答を有すると予測すること;並びに/又は
(ii)a.各ペプチド若しくはコードされているペプチドが、前記被験体の少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープである少なくとも1つのアミノ酸配列を含んでいると判定し;そして、
b.前記被験体が、前記医薬組成物の各ペプチド、又は前記キットの各ペプチド、ポリ核酸、若しくはベクターに対してCD4+T細胞応答を有すると予測すること
を含む方法。 A method of predicting that a particular human subject will have a CD8+ T cell response and/or a CD4+ T cell response to each peptide or encoded peptide of the pharmaceutical composition or kit of claim 5, comprising:
(i) a. determining that each peptide or encoded peptide contains at least one amino acid sequence that is a T-cell epitope capable of binding to at least three HLA class II molecules of said subject; and
b. predicting that said subject will have a CD8+ T cell response to each peptide of said pharmaceutical composition, or each peptide, polynucleic acid or vector of said kit; and/or (ii) a. determining that each peptide or encoded peptide contains at least one amino acid sequence that is a T-cell epitope capable of binding to at least three HLA class II molecules of said subject; and
b. predicting that said subject will have a CD4+ T cell response to each peptide of said pharmaceutical composition, or each peptide, polynucleic acid or vector of said kit.
a.請求項1に記載の2種以上のペプチド又は請求項1に記載の少なくとも2種のペプチドをコードしている請求項2に記載の1つ以上のポリ核酸若しくはベクターを選択することであって、各ペプチド又はコードされているペプチドが、前記特定のヒト被験体の少なくとも3つのHLAクラスIアレルに結合することができるT細胞エピトープ及び/又は少なくとも3つのHLAクラスIIアレルに結合することができるT細胞エピトープを含む配列番号107、1~106、108~2786及び/又は5432~5931から選択されるアミノ酸配列を含むことと;
b.工程aで選択された2種以上のペプチド、又は1つ以上のポリ核酸若しくはベクターを含む、医薬組成物又はキットを調製することと
を含む方法。 A method of preparing a pharmaceutical composition or kit for use in a method of treating cancer in a particular human subject, comprising:
a. selecting two or more peptides according to claim 1 or one or more polynucleic acids or vectors according to claim 2 encoding at least two peptides according to claim 1, each peptide or encoded peptide is a T cell epitope capable of binding at least three HLA class I alleles and/or T capable of binding at least three HLA class II alleles of said particular human subject; comprising an amino acid sequence selected from SEQ ID NOs : 107, 1-106 , 108-2786 and/or 5432-5931 that comprises a cellular epitope;
b. preparing a pharmaceutical composition or kit comprising the two or more peptides or one or more polynucleic acids or vectors selected in step a.
(i)それぞれHLAクラスI遺伝子型及び/又はHLAクラスII遺伝子型によって定義される複数の被験体を含むモデルヒト集団を選択又は定義することと;
(ii)前記モデル集団の各被験体について、
(a)前記被験体の少なくとも3つのHLAクラスI分子に結合することができるT細胞エピトープである前記標的ポリペプチドのアミノ酸配列;
(b)前記被験体の少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープである前記標的ポリペプチドのアミノ酸配列;
(c)前記被験体の少なくとも3つのHLAクラスI分子に結合することができるT細胞エピトープ及び前記被験体の少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープを含む前記標的ポリペプチドのアミノ酸配列;又は
(d)
a.少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープであり;かつ
b.前記被験体の少なくとも3つのHLAクラスI分子に結合することができるT細胞エピトープであるアミノ酸配列を含む
前記標的ポリペプチドのアミノ酸配列
を同定することと;
(iii)9~50アミノ酸のポリペプチド断片ウィンドウ長を選択することと;
(iv)
(a)工程(iii)で選択された長さを有し;かつ
(b)前記モデル集団で最も高い割合の被験体において工程(ii)(a)~(d)のいずれか1つで同定されたアミノ酸配列を含む、
前記標的ポリペプチドの断片を同定することと;
(v)任意で、工程(iv)で同定された断片を追加の所定の基準に対して試験し、更なる所定の基準を満たさない場合は前記断片を拒絶し、工程(iv)を繰り返して、
(a)工程(iii)で選択された長さを有し;かつ
(b)前記モデル集団で次に高い割合の被験体において工程(iv)で同定されたアミノ酸配列を含む
前記標的ポリペプチドの代替断片を同定することと;
(vi)任意で、1つ以上の更なるラウンドで工程(iv)及び更に任意で工程(v)を繰り返すことであって、各ラウンドにおいて前記標的ポリペプチドの更なる断片が同定され、各ラウンドにおいて、前のラウンドのいずれかの工程(iv)で選択され、工程(v)で拒絶されなかった断片のいずれかが、その被験体について工程(ii)で同定されたアミノ酸配列を含む場合、被験体を前記モデル集団から除外することと;
(vii)ペプチド、ペプチドをコードしているポリ核酸若しくはベクター、ペプチドのパネル、又はペプチドのパネルをコードしている1つ以上のポリ核酸若しくはベクターを設計又は調製することであって、各ペプチドが、工程(iv)、(v)、又は(vi)で同定された前記標的ポリペプチド断片のうちの1つ以上を含み、任意で、前記ポリペプチド断片が、N及び/又はC末端で、前記標的ポリペプチド抗原の配列の一部ではない追加のアミノ酸に隣接していることと
を含む方法。 A peptide, or a polynucleic acid or vector encoding a peptide, or a panel of peptides, or one or more polypeptides encoding a panel of peptides, for use in a method of inducing a T cell response to a target polypeptide. A method of designing or preparing a nucleic acid or vector, comprising:
(i) selecting or defining a model human population comprising a plurality of subjects each defined by HLA class I genotype and/or HLA class II genotype;
(ii) for each subject in the model population,
(a) an amino acid sequence of said target polypeptide that is a T cell epitope capable of binding to at least three HLA class I molecules of said subject;
(b) an amino acid sequence of said target polypeptide that is a T-cell epitope capable of binding to at least three HLA class II molecules of said subject;
(c) said target polypeptide comprising a T cell epitope capable of binding to at least three HLA class I molecules of said subject and a T cell epitope capable of binding to at least three HLA class II molecules of said subject; or (d) the amino acid sequence of
a. a T-cell epitope capable of binding to at least three HLA class II molecules; and b. identifying an amino acid sequence of said target polypeptide that includes an amino acid sequence that is a T cell epitope capable of binding to at least three HLA class I molecules of said subject;
(iii) selecting a polypeptide fragment window length of 9-50 amino acids;
(iv)
(a) having the length selected in step (iii); and (b) identified in any one of steps (ii) (a)-(d) in the highest percentage of subjects in said model population. comprising an amino acid sequence identified by
identifying fragments of said target polypeptide;
(v) optionally testing the fragments identified in step (iv) against additional predetermined criteria, rejecting said fragments if they do not meet further predetermined criteria, and repeating step (iv); ,
(a) having the length selected in step (iii); and (b) comprising the amino acid sequence identified in step (iv) in the next highest percentage of subjects in the model population. identifying alternative fragments;
(vi) optionally repeating step (iv) and further optionally step (v) in one or more further rounds, wherein in each round a further fragment of said target polypeptide is identified; in any of the fragments selected in step (iv) of the previous round that were not rejected in step (v) contain the amino acid sequence identified in step (ii) for that subject, excluding subjects from the model population;
(vii) designing or preparing a peptide, a polynucleic acid or vector encoding a peptide, a panel of peptides, or one or more polynucleic acids or vectors encoding a panel of peptides, each peptide comprising , one or more of said target polypeptide fragments identified in steps (iv), (v) or (vi), optionally wherein said polypeptide fragments are N- and/or C-terminally linked to said flanking additional amino acids that are not part of the sequence of the target polypeptide antigen.
(a)病原生物、ウイルス、又はがん細胞によって発現されるポリペプチドの断片であり;かつ
(b)前記被験体の少なくとも3つのHLAクラスI分子に結合することができるT細胞エピトープ又は前記被験体の少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープである
アミノ酸配列を含む、請求項13又は14に記載の方法。 15. Designed or prepared according to the method of claim 13 or 14 for use in a method of vaccinating, providing immunotherapy, or inducing a cytotoxic and/or helper T cell response in a subject further comprising selecting one or more peptides, polynucleic acids or vectors, optionally each of said one or more peptides or encoded peptides comprising:
(a) a fragment of a polypeptide expressed by a pathogenic organism, virus, or cancer cell; and (b) a T cell epitope capable of binding to at least three HLA class I molecules of said subject or said subject. 15. The method of claim 13 or 14, comprising amino acid sequences that are T cell epitopes capable of binding to at least three HLA class II molecules of the body.
(a)9~50アミノ酸長であり;かつ
(b)前記1つ以上の標的ポリペプチドの断片を含み、前記断片が、治療企図ヒト集団の被験体の少なくとも10%において、
a.前記被験体の少なくとも3つのHLAクラスI分子に結合することができるT細胞エピトープである標的ポリペプチドのアミノ酸配列;
b.前記被験体の少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープである標的ポリペプチドのアミノ酸配列;
c.前記被験体の少なくとも3つのHLAクラスI分子に結合することができるT細胞エピトープ及び前記被験体の少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープを含む標的ポリペプチドのアミノ酸配列;又は
d.
i.少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープであり;かつ
ii.前記被験体の少なくとも3つのHLAクラスI分子に結合することができるT細胞エピトープであるアミノ酸配列を含む
標的ポリペプチドのアミノ酸配列
を含むアミノ酸配列を含む、ペプチドのパネル、又はペプチドのパネルをコードしている1つ以上のポリ核酸若しくはベクター。 A panel of peptides, or one or more polynucleic acids or vectors encoding a panel of peptides, for use in a method of inducing a T cell response against one or more target polypeptides in a subject of a target human population. wherein each of said peptides, or encoded peptides,
(a) is 9 to 50 amino acids in length; and (b) comprises a fragment of said one or more target polypeptides, said fragment comprising, in at least 10% of the subjects of the intended treatment human population,
a. an amino acid sequence of a target polypeptide that is a T-cell epitope capable of binding to at least three HLA class I molecules of said subject;
b. an amino acid sequence of a target polypeptide that is a T-cell epitope capable of binding to at least three HLA class II molecules of said subject;
c. an amino acid sequence of a target polypeptide comprising a T cell epitope capable of binding to at least three HLA class I molecules of said subject and a T cell epitope capable of binding to at least three HLA class II molecules of said subject; or d.
i. is a T-cell epitope capable of binding to at least three HLA class II molecules; and ii. encoding a panel of peptides, or a panel of peptides, comprising an amino acid sequence comprising an amino acid sequence of a target polypeptide comprising an amino acid sequence that is a T cell epitope capable of binding to at least three HLA class I molecules of said subject; one or more polynucleic acids or vectors.
(a)病原生物、ウイルス、又はがん細胞によって発現されるポリペプチドの断片であり;かつ
(b)前記被験体の少なくとも3つのHLAクラスI分子に結合することができるT細胞エピトープ又は前記被験体の少なくとも3つのHLAクラスII分子に結合することができるT細胞エピトープである
アミノ酸配列を含む、請求項20に記載の方法。
one or more or each of said peptide or said encoded peptide is
(a) a fragment of a polypeptide expressed by a pathogenic organism, virus, or cancer cell; and (b) a T cell epitope capable of binding to at least three HLA class I molecules of said subject or said subject. 21. The method of claim 20, comprising amino acid sequences that are T-cell epitopes capable of binding to at least three HLA class II molecules of the body.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1814362.8A GB201814362D0 (en) | 2018-09-04 | 2018-09-04 | Composition and process for preparing vaccine |
GB1814362.8 | 2018-09-04 | ||
PCT/EP2019/073481 WO2020048995A1 (en) | 2018-09-04 | 2019-09-03 | Process for preparing vaccine compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021535749A JP2021535749A (en) | 2021-12-23 |
JPWO2020048995A5 true JPWO2020048995A5 (en) | 2022-11-28 |
Family
ID=63920945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021512906A Pending JP2021535749A (en) | 2018-09-04 | 2019-09-03 | Process for preparing vaccine composition |
Country Status (17)
Country | Link |
---|---|
US (3) | US20200069786A1 (en) |
EP (1) | EP3847185A1 (en) |
JP (1) | JP2021535749A (en) |
KR (1) | KR20210086610A (en) |
CN (1) | CN113383009A (en) |
AU (1) | AU2019334261A1 (en) |
BR (1) | BR112021004075A2 (en) |
CA (1) | CA3110923A1 (en) |
CL (1) | CL2021000534A1 (en) |
CO (1) | CO2021004028A2 (en) |
EA (1) | EA202190669A1 (en) |
GB (1) | GB201814362D0 (en) |
IL (1) | IL281220A (en) |
MA (1) | MA53544A (en) |
MX (1) | MX2021002543A (en) |
SG (1) | SG11202101881UA (en) |
WO (1) | WO2020048995A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110651189A (en) | 2017-03-03 | 2020-01-03 | 特雷斯生物公司 | Peptide vaccine |
GB201804468D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
MX2021002449A (en) | 2018-09-04 | 2021-08-05 | Treos Bio Ltd | Peptide vaccines. |
GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
US20230190902A1 (en) * | 2020-05-29 | 2023-06-22 | Children's National Medical Center | Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame |
CN111617238B (en) * | 2020-06-02 | 2022-12-13 | 苏州药明康德新药开发有限公司 | Polypeptide vaccine preparation for treating tumor of mouse CT26 colorectal cancer and preparation method thereof |
EP3945320A1 (en) * | 2020-07-29 | 2022-02-02 | Corporació Sanitària Parc Taulí | Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein |
CA3196679A1 (en) * | 2020-10-28 | 2022-05-05 | Jan Alenfall | Peptides for use in skin and hair pigmentation |
CN113144181B (en) * | 2021-04-20 | 2022-07-19 | 徐州医科大学 | B7H 3-targeted DNA vaccine, and preparation method and application thereof |
CN114195861A (en) * | 2022-01-05 | 2022-03-18 | 许昌学院 | Affinity peptides |
CN115785204B (en) * | 2022-06-10 | 2024-02-13 | 河北博海生物工程开发有限公司 | Lung cancer specific molecular target 08 and application thereof |
CN115785211A (en) * | 2022-06-10 | 2023-03-14 | 河北博海生物工程开发有限公司 | Lung cancer specific molecular target 04 and application thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
FR2791895B1 (en) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE |
AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
GB0520067D0 (en) * | 2005-10-01 | 2005-11-09 | Cancer Rec Tech Ltd | Treatment of cancer |
WO2012051282A2 (en) * | 2010-10-14 | 2012-04-19 | The Ohio State University Research Foundation | Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy |
GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
EP3369431A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Vaccine |
EP3370065A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Immunogenic peptides |
CN110651189A (en) | 2017-03-03 | 2020-01-03 | 特雷斯生物公司 | Peptide vaccine |
-
2018
- 2018-09-04 GB GBGB1814362.8A patent/GB201814362D0/en not_active Ceased
-
2019
- 2019-09-03 CA CA3110923A patent/CA3110923A1/en active Pending
- 2019-09-03 WO PCT/EP2019/073481 patent/WO2020048995A1/en active Application Filing
- 2019-09-03 MX MX2021002543A patent/MX2021002543A/en unknown
- 2019-09-03 SG SG11202101881UA patent/SG11202101881UA/en unknown
- 2019-09-03 MA MA053544A patent/MA53544A/en unknown
- 2019-09-03 KR KR1020217009975A patent/KR20210086610A/en active Search and Examination
- 2019-09-03 AU AU2019334261A patent/AU2019334261A1/en active Pending
- 2019-09-03 EA EA202190669A patent/EA202190669A1/en unknown
- 2019-09-03 CN CN201980071000.1A patent/CN113383009A/en active Pending
- 2019-09-03 US US16/559,430 patent/US20200069786A1/en not_active Abandoned
- 2019-09-03 JP JP2021512906A patent/JP2021535749A/en active Pending
- 2019-09-03 EP EP19765219.1A patent/EP3847185A1/en active Pending
- 2019-09-03 BR BR112021004075-7A patent/BR112021004075A2/en unknown
-
2021
- 2021-02-26 US US17/249,362 patent/US20210236611A1/en not_active Abandoned
- 2021-03-03 IL IL281220A patent/IL281220A/en unknown
- 2021-03-04 CL CL2021000534A patent/CL2021000534A1/en unknown
- 2021-03-30 CO CONC2021/0004028A patent/CO2021004028A2/en unknown
-
2022
- 2022-02-08 US US17/650,360 patent/US20220160854A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2836273T3 (en) | Cancer treatment method | |
US11007223B2 (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
Mashino et al. | Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas | |
JP2016156828A5 (en) | ||
JP2020500523A5 (en) | ||
KR20180118702A (en) | Peptides, combinations of peptides and cell-based medicaments for use in immunotherapy for bladder cancer and other cancers | |
UA124575C2 (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
CN109152813B (en) | Novel peptides, peptide compositions as targets for gallbladder and bile duct cancer and other cancer immunotherapy | |
TW201738274A (en) | Uterine cancer treatments | |
JPWO2020048995A5 (en) | ||
JP2021500406A5 (en) | ||
MX2022011411A (en) | Antigen binding proteins specifically binding mage-a. | |
JP2023100687A (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
JP7026970B2 (en) | Peptides and combinations of peptides for use in immunotherapy for leukemia and other cancers | |
AU2020264365C1 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
JP2019506154A (en) | Compositions and libraries comprising recombinant T cell receptors and methods of using recombinant T cell receptors | |
CA3108578A1 (en) | B*44 restricted peptides for use in immunotherapy against cancers and related methods | |
IL292864A (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
IL254129B1 (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
IL309715A (en) | Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods | |
JPWO2020193767A5 (en) | ||
JP2021045124A (en) | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers | |
RU2022107909A (en) | IMMUNOTHERAPY TARGETED TUMOR NEOANTIGEN PEPTIDES | |
RU2021106561A (en) | T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | |
TH1901003352A (en) | New T cell receptors and immunotherapy using the same |